Mechanisms of sars-COV-2-mediated disruption of trophoblast dynamics

Active Grant Awarded

Award ID
K99HD119264
Recipient
Awarding agency
Obligated
$125,187

Award facts

Completion date 9% complete
Place of performance
Houston, TX 77030, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through the National Institute of Child Health and Human Development, awarded Pennsylvania State University, doing business as Penn State Milton S. Hershey Medical Center, $125,187 on Sep 17, 2026, under Grant K99HD119264, a grant under Child Health and Human Development Extramural Research (CFDA 93.865). The award funds research on how SARS-CoV-2 disrupts placental function, centered on the viral accessory protein ORF3A and its effects on trophoblast cells. Its stated aims are to develop targeted small molecule inhibitors and clinically relevant vascularized organoid models for continued study. Aim 1 will characterize how ORF3A activates secretory autophagy in trophoblast cell lines and organoids transduced with ORF3A and exposed to live SARS-CoV-2, isolating extracellular vesicles and profiling their cargo proteome by mass spectrometry. The period of performance ends Aug 31, 2028, and the place of performance is Houston, TX 77030, USA.

Description

Abstract
Infections with sars-COV-2 during pregnancy adversely affect placental physiology, increasing health risks for the mother and fetus. Sars-COV-2 can infect maternal and fetal cells in the placenta, however, there is a significant GAP in understanding specifically how sars-COV-2 infection impacts placental homeostasis and function. The overall objective of this proposal is to investigate the intercellular communication pathways in placental homeostasis affected by sars-COV-2 infection and develop targeted small molecule inhibitors and clinically relevant vascularized organoid models for continued study. Key to this investigation is the sars-COV- 2 accessory protein ORF3A. Preliminary findings indicate that 1) sars-COV-2 exposed placentas have pathologies like increased syncytial knots and defective autophagy; 2) sars-COV-2 ORF3A induces increased extracellular vesicle (EV) secretion via secretory autophagy; 3) ORF3A induces formation of tunneling nanotubes (TNTS) to potentially spread viral proteins to non-permissive cells; 4) stem cell-derived trophoblast organoids (SC-TOS) transfected with ORF3A+ lentivirus show impaired syncytialization and increased TNT formation; and 5) ORF3A directly interacts with ZO-1, a junctional protein essential for syncytial trophoblast maturation and placental barrier integrity. This supports the hypothesis that sars-COV-2 reprograms trophoblast cell physiology and function through ORF3A, enhancing extracellular vesicle secretion and inducing TNT formation, thus spreading viral proteins across placental cells. Aim 1 will investigate the molecular mechanisms by which sars-COV-2 ORF3A activates secretory autophagy using trophoblast cell lines and organoids transduced with ORF3A and live sars-COV-2 infection. EVS will be isolated and distinct cargo proteome from ORF3A-transfected cells/organoids will be characterized using mass spectroscopy, and specific residues involved in EV secretion will be identified via site-directed mutagenesis. Functional studies will assess if these EVS impair trophoblast function. Molecular docking and simulation of small molecule fragment-based libraries will be used to characterize specific inhibitors for ORF3A and sars-COV-2. Aim 2 will determine the mechanism of TNT formation by sars-COV-2 ORF3A and its impact on host cell interaction. The ORF3A regions that induce TNTS in trophoblast cells will be identified by creating constructs with deleted motifs and quantifying TNT formation via confocal microscopy. ORF3A's interaction with RHO-gtpases will be investigated for actin cytoskeleton remodeling using pull-down assays, gene knock-down techniques, and confocal microscopy. These two aims will be pursued during the final postdoctoral training period of the K99 phase. Aim 3 seeks to develop clinically relevant human placenta-derived organoids from sars-COV-2 exposed tissues. These organoids will be tested for modulation of autophagy, EV and TNT pathways. The small molecules from in vitro high throughput screening of a DNA-encoded library will be tested in these organoid models. Microfluidic-based chips will be used to develop vascularized placenta organoid models to map dynamic changes due to sars-COV-2 infection.

Quick answers

Who received award K99HD119264?

K99HD119264 was awarded to Pennsylvania State University by National Institute of Child Health and Human Development (National Institutes of Health) on September 17, 2026.

How much is award K99HD119264 worth?

$125,187 has been obligated on K99HD119264.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award